OPPapers.com Essay Index >> Business >> Biopure
We have many free term papers and essays on Biopure. We also have a wide variety of research papers and book reports available to you for free. You can browse our collection of term papers or use our search engine.
biopure swot analysis Biopure's two products, Hemopure for human use, and Oxyglobin for animal veterinary use, both represented a new blood substitute based treatment
Biopure BIOPURE PAPER Recommendation: I strongly recommend that Biopure launch Oxyglobin immediately at a price of $150.00 and initially focus principally on large
Biopure BIOPURE CORPORATION ? BLOOD SUSTITUTE DECISION By: Rob Campbell, John Nicolaus, Satya Rao and Jim Zinski Introduction: We have reviewed the available information
BioPure case BioPure Corporation, which was founded in 1984 by entrepreneurs Carl Rausch and David Judelson, is a privately owned biopharmaceutical firm specializing
Biopure Oxyglobin Launch Company: Biopure's greatest strength lies in its ability to market its blood substitute technology for both animal and human use. Further,
Submitted by talumbar on November 8, 2007
Category: Business
Words: 1755 | Pages: 8
Views: 269
Popularity Rank: 52,371
Average Member Grade: N/A (Add a Comment / Grade this Paper)
Problem Statement Biopure (BPC), is a small and private developer of human (Hemopure) and animal (Oxyglobin) blood substitutes. Biopure is faced with the decision of whether to immediately launch Oxyglobin (Og) or wait until after the launch of hemapure (Hp), which will be in about two years following FDA approval. If they decide to launch they must determine their pricing strategy. The concern is that launching Oxyblobin would create an obstacle to the pricing of Hemopure, the company's initial product focus.
Market Analysis The combination of lengthy approval process of the FDA, intellectual property laws, and R&D capital requirements, poses a high entry barrier in the blood substitute markets. The human market is expected to experience moderate future growth affected by an increase in population, and in particular the proportion of older citizens. Also, the human market suffers from uneven seasonal variations in blood supply and demand. There is higher demand in summer and winter holiday seasons and this demand is exacerbated by lower donations. Although the total potential size of the human market in the US is 13.5 million units (Exhibit 1), Hemopure's long shelf life and lack of need for refrigeration makes it particularly suitable for trauma cases estimated at 2 million units.
The existing system for supplying animal blood is poor at matching animal blood types and it is relatively costly, leading to an underserved market. Veterinarians use approximately 350,000 units of blood per year in canine transfusions, all of which could be captured by Og. The potential market size is estimated at only 2.3 million (Exhibit 2). Even with the smaller demand figure, however, BPC's capacity of 300,000 would still leave some excess demand. This, along with minimal threat of entry (due to R&D and FDA approval processes) results in the potential for maintaining high prices for Og.
Company Analysis BPC is a manufacturer of blood...
You must Login to view the entire paper.
If you are not a member yet, Sign Up for free!